ClinicalTrials.gg

Program

GSK-3965193

In GlaxoSmithKline’s pipeline, PAPD5/PAPD7 inhibitor. Its studies are mostly in Hepatitis B, Chronic, led by GlaxoSmithKline.

Furthest: phase 2, since Apr 8, 20221 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline10 open or runningphase 2since Apr 8, 2022Apr 8, 2022none ahead
  • Named in GlaxoSmithKline’s own pipeline as GSK3965193, phase 1, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 8, 2022First study: phase 2 study in Hepatitis BFirst studyNCT05330455 · 74 enrolled · Canada, France, Italy and more

TargetBeta

“PAPD5/PAPD7 inhibitor”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05330455Hepatitis B · Canada, France, Italy and more2TerminatedMay 19, 202574

How it is read

Names in the registry

  • “GSK3965193”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.